{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:09Z","timestamp":1793406849773,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.kint.2025.04.031","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T18:56:08Z","timestamp":1749236168000},"page":"927-937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody \u2265 99.9%"],"prefix":"10.1016","volume":"108","author":[{"given":"David","family":"Cucchiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mancebo-Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Meneghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"P\u00e9rez-Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Romero","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Redondo-Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolt","family":"Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Moreso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-3016","authenticated-orcid":false,"given":"Fritz","family":"Diekmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.04.031_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/TP.0000000000004824","article-title":"Improving the access of highly sensitized patients to kidney transplantation from deceased donors: the Spanish PATHI program with allocation based on the virtual crossmatch","volume":"108","author":"Valentin","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.04.031_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10511","article-title":"European guideline for the management of kidney transplant patients with HLA antibodies: by the European Society for Organ Transplantation Working Group","volume":"35","author":"Mamode","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.04.031_bib3","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.04.031_bib4","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/TP.0000000000003496","article-title":"Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes)","volume":"105","author":"Jordan","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.04.031_bib5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.04.031_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13906","article-title":"The shared epitope phenomenon-a potential impediment to virtual crossmatch accuracy","volume":"34","author":"Garcia-Sanchez","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.04.031_bib7","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.04.031_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1600-6143.2007.02072.x","article-title":"Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation","volume":"8","author":"Lefaucheur","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.04.031_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.kint.2017.07.018","article-title":"Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients","volume":"93","author":"Heidt","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.04.031_bib10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ekir.2018.03.015","article-title":"Combining sensitive crossmatch assays with donor\/recipient human leukocyte antigen eplet matching predicts living-donor kidney transplant outcome","volume":"3","author":"Meneghini","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.04.031_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iji.12658","article-title":"Predicting flow cytometry crossmatch results from single-antigen bead testing","volume":"51","author":"Flynn","year":"2024","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.kint.2025.04.031_bib12","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1097\/TP.0000000000004586","article-title":"Virtual and reality: an analysis of the UCLA virtual crossmatch exchanges","volume":"107","author":"Locke","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.04.031_bib13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2215\/CJN.05930615","article-title":"Approach to the highly sensitized kidney transplant candidate","volume":"11","author":"Keith","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.04.031_bib14","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1097\/TP.0000000000001650","article-title":"Long-term outcomes of kidney transplantation in patients with high levels of preformed DSA: the Necker High-Risk Transplant Program","volume":"101","author":"Amrouche","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.04.031_bib15","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.04.031_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12745","article-title":"Anti-HLA donor-specific antibodies are not created equally: don't forget the flow\u2026","volume":"29","author":"Bachelet","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.04.031_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11244","article-title":"Imlifidase for kidney transplantation of highly sensitized patients with a positive crossmatch: the French consensus guidelines","volume":"36","author":"Couzi","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.04.031_bib18","unstructured":"British Transplantation Society. UK guideline on imlifidase enabled deceased donor kidney transplantation. Accessed July 3, 2025. https:\/\/bts.org.uk\/uk-guideline-on-imlifidase-enabled-deceased-donor-kidney-transplantation\/"},{"key":"10.1016\/j.kint.2025.04.031_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.04.031_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.0000000000000095","article-title":"Expression of class II human leukocyte antigens on human endothelial cells shows high interindividual and intersubclass heterogeneity","volume":"34","author":"B\u00e9land","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.04.031_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203381","article-title":"The prevalence of antibodies against the HLA-DRB3 protein in kidney transplantation and the correlation with HLA expression","volume":"13","author":"Habets","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.04.031_bib22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1500140","article-title":"High HLA-DP expression and graft-versus-host disease","volume":"373","author":"Petersdorf","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.04.031_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.humimm.2018.02.014","article-title":"Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes","volume":"79","author":"Redondo-Pach\u00f3n","year":"2018","journal-title":"Hum Immunol"},{"key":"10.1016\/j.kint.2025.04.031_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.trim.2013.07.002","article-title":"Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?","volume":"29","author":"Crespo","year":"2013","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.kint.2025.04.031_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1600-6143.2010.03421.x","article-title":"Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy","volume":"11","author":"Willicombe","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.04.031_bib26","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ndt\/gfr429","article-title":"Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation","volume":"27","author":"Caro-Oleas","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.04.031_bib27","article-title":"Preformed donor-specific antibodies against HLA class II and graft outcomes in deceased-donor kidney transplantation","volume":"5","author":"Uffing","year":"2019","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2025.04.031_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005790","article-title":"The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation - data from the Swiss transplant cohort study","volume":"13","author":"Frischknecht","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.04.031_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajt.2022.11.009","article-title":"Sensitization in transplantation: Assessment of Risk 2022 Working Group Meeting Report","volume":"23","author":"Tambur","year":"2023","journal-title":"Am J Transplant"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825004272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825004272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:18:09Z","timestamp":1760825889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825004272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0085253825004272"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.04.031","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated Panel Reactive Antibody \u2265 99.9%","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.08.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}